To view the video full screen, click on the small button next to the volume control in the lower right hand corner.
AUTHORS: K. Vanderkerken,1 T. Bos,1 E. Van Valckenborgh,1 E. Menu,1 I. Van Riet,1 H. De Raeve,2 P. Croucher3 B. Van Camp1
1Vrije Universiteit Brussel (VUB), Department Hematology and Immunology, Brussels, Belgium; 2University Hospital Antwerp, Department of Pathology, Antwerp, Belgium; 3University of Sheffield Medical School, Academic Unit of Bone Biology, Sheffield, UK
by Lynne Lederman, PhD
Dr. Vanderkerken presented an overview of the current animal models of multiple myeloma. Each model has its advantages and limitations. Whereas in vitro studies allow a two dimensional experimental approach to studying the disease, in vivo models provide a three dimensional approach. The ideal animal model of myeloma is one that reproduces the key features of the disease, including myeloma cells in the bone marrow, interactions with the bone marrow micro environment, and development of done disease. Models provide the tools to study tumor burden, bone disease, and angiogenesis, and allow isolation of different cellular compartments. Many current models are based on the use of mice with severe combined immunodeficiency (SCID), with xenografts of myeloma cells or human or rabbit fetal bone implanted with myeloma cells. Another model uses myleoma cells in hollow fibers. There are also transgene-based models. Dr. Vanderkerken emphasized that given the advantages and limitations of current models, it is important for researchers to base their selection on the questions they want to ask.